The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at evading eradication ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

The initiative, funded by a $12 million grant from the National Institute on Drug Abuse, will evaluate how people with ...

Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

WHO emphasizes integrating surveillance into national STI programs. Zoliflodacin, a novel antimicrobial agent, shows promise in treating gonorrhea, demonstrating non-inferiority to ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...

The disclosure by director of Women’s Health at the Ministry of Health Dr Adesh Sirjusingh that syphilis infections among pregnant women are on the rise in Trinidad and Tobago is ...